Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?

Journal of viral hepatitis - 1 Oct 2012

Holmes J A, Desmond P V, Thompson A J

Abstract excerpt

IL28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC) treated with pegylated interferon (peg-IFN) and ribavirin (RBV). Patients carrying the good response genotype have a two- to threefold higher chance of SVR than those with a poor response genotype, manifest as dramatically improved early...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Interleukins

Share to Polymorphism, Genetic

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 22967098
DOI: 10.1111/jvh.12003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?PMID 22967098Read ↗

IL28B in the era of direct-acting antivirals for hepatitis C.Semantic proximity Read ↗

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Semantic proximity Read ↗

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?Semantic proximity Read ↗

Role of IL28B for chronic hepatitis C treatment toward personalized medicine.Semantic proximity Read ↗

IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.Semantic proximity Read ↗

Effect of IL28B genotype on hepatitis B and C virus infection.Semantic proximity Read ↗

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Semantic proximity Read ↗

IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?Semantic proximity Read ↗

Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?Semantic proximity Read ↗

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.Semantic proximity Read ↗

Interleukin 28B genetic polymorphism and hepatitis B virus infection.Semantic proximity Read ↗

Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.